New Delhi, Sept. 17, 2022 (GLOBE NEWSWIRE) — The global infectious disease point-of-care (PoC) testing market is booming mainly due to the rapidly increasing demand for PoC testing kits for the diagnosis of increasing prevalence of infectious diseases such as HIV, flu, RSV and Covid in the global population.
BlueWeave Consultinga leading strategic consulting and market research firm, in its recent study estimated the size of Global Point-of-Care (PoC) Infectious Disease Testing Market. at USD 1.4 billion in 2021. BlueWeave expects the Global Point of Care (PoC) Infectious Disease Testing market to expand at an impressive CAGR of 17.4% between 2022 and 2028 to reach size of US$ 4.22 billion by 2028. Major growth factors of the market expansion includes increasing number of people worldwide affected by various infectious diseases such as HIV, Covid, influenza and RSV.
Global Point-of-Care (PoC) Infectious Disease Testing Market – Technological Advances
Owing to the robust product portfolios and impressive distribution networks of major corporations in developed and developing countries, the market for infectious disease diagnostics is semi-consolidated. Strategic alliances between major players in the sector and introduction of diagnostic products are expected to boost the growth of the companies and increase their market share. However, future market opportunities allow a number of local competitors to enter in the coming years. By 2028, the market will be slightly fragmented as a result. For example, Precipio Inc. and ADS Biotech engaged in a strategic alliance in July 2020 to develop a lateral flow immunoassay-based test for the detection of COVID-19. It has received EUA approval to distribute the kits to physician laboratories, retail pharmacies and direct to consumers.
Request a sample report @ https://www.blueweaveconsulting.com/report/point-of-care-infectious-disease-testing-market/report-sample
Global Point-of-Care (PoC) Infectious Disease Testing Market – Growing Demand
The prevalence of infectious diseases, including HIV, influenza, and RSV, is increasing worldwide, further increasing the rate at which patients are diagnosed. For example, the United Nations Program on HIV/AIDS (UNAIDS) estimated that 38 million people worldwide were diagnosed with HIV/AIDS in 2019. Additionally, a study published by the World Health Organization (WHO) estimated that approximately 10 million people around the world were infected by TB in 2018. As a result, during the period under analysis, the increasing prevalence of infectious diseases would increase the need for PoC devices for their diagnosis and in turn support the expansion of the market.
Global Point-of-Care (PoC) Infectious Disease Testing Market – By Technology
Agglutination test, flow test/immunoconcentration test, molecular diagnostics, and others are the technology-based segments of the Global Point-of-Care (PoC) infectious disease testing market. In 2020, the lateral flow immunoassay market category represented a one-sided market share. Faster diagnostics and availability of test kits in decentralized settings are responsible for the superiority. Additionally, the segment has grown as a result of more product launches as a result of COVID-19.
Increased use of innovative tests such as RT-PCR and ELISA in PoC testing kits for infectious diseases is expected to drive the molecular diagnostics market through 2028. Furthermore, increasing FDA approvals are likely to accelerate the revenue growth of the segment. Furthermore, the flow test/immunoconcentration assay market is expected to expand at a significant CAGR during the forecast period as more industry players work on introducing complex flow-based kits in the international market. Moreover, throughout the analysis period, the agglutination test segment is expected to advance due to the growing knowledge about the use of agglutination tests for the diagnosis of infectious diseases.
Please visit the press release: https://www.blueweaveconsulting.com/press-release/point-of-care-poc-infectious-disease-testing-market-surging-over-4x-touching-usd-4-22-billion-by-2028
Due to factors such as the presence of significantly large companies and well-established healthcare system, North America dominates the infectious disease PoC testing market with the US accounting for the highest revenue share. Additionally, the expected revenue share is supported by the introduction of technological advancements in the US. Meanwhile, due to rising R&D investment in patient-oriented institutions in Japan and China, the Asia Pacific (APAC) region is expected to expand at the fastest pace. Additionally, variables expected to drive regional success include the rapidly increasing burden of chronic infectious diseases and the existence of government initiatives designed to promote early detection. Businesses in APAC are concentrating on creating new analytics. For example, in May 2017, One BioMed and Singapore’s A*Star’s Genome Institute established a joint laboratory venture to create molecular diagnostic assays. The goal of this collaboration is to create analytics for the Asian market for clinical diagnostics of infectious diseases. Among these tests are those for juvenile respiratory infections, mosquito-borne diseases and drug-resistant tuberculosis.
Impact of COVID-19 on the Global Point-of-Care (PoC) Infectious Disease Testing Market.
The COVID-19 pandemic has had a moderate impact on pharmaceutical companies and research organizations that are concentrating on the creation of POC kits for the diagnosis of COVID-19. The launch of cutting-edge kits with quick turnaround time will accelerate the market expansion during the period under analysis. For example, BD (Becton, Dickinson and Company) announced in July 2020 that the USFDA had approved the use of an Emergency Use Authorization (EUA) for a rapid point-of-care test for SARS-CoV-2 for use with its widely used BD Veritor system Plus. However, due to supply chain disruptions and the implementation of lockdown measures, demand and sales of diagnostic products related to infectious diseases such as MRSA (methicillin-resistant Staphylococcus aureus), HIV (human immunodeficiency virus) and CDI (infection with Clostridium difficile) have decreased. In addition, the revenues of companies including Roche and Abbott were affected by the reduction in routine testing of diagnostic procedures for various diseases. However, the market is expected to recover quickly in the post-COVID-19 pandemic era.
Don’t miss the business opportunity in Global Infectious Disease Testing (PoC) Market.. Consult our analysts to get important information and facilitate the growth of your business.
The competitive environment
Alere, Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., Siemens Healthineers, BD & Co., Chembio Diagnostics Inc., Trinity Biotech, Cardinal Health, Quest Diagnostics Inc., Bio-Rad Labs Inc., bioMérieux SA , Sight Diagnostics Ltd., Gene POC, Trivitron Healthcare, OJ-Bio Ltd. and Ortho-Clinical Diagnostics are leading companies in the Global Point of Care (PoC) infectious disease testing market. Major players are currently forming strategic alliances with other established and emerging organizations. The goals of the partnerships are to strengthen market presence by creating a robust product portfolio that supports precision diagnostics.
- Chembio Diagnostics, Inc., released a PoC COVID-19/Influenza A&B rapid test in April 2021. Test results are available in 15 minutes. Roche launched the Cobas SARS-CoV-2 Variant Set 1 Test in March 2021. The test is designed to detect variants of COVID-19 that are present in the UK, South Africa and Brazil.
Scope of the report
|Years examined||Historical data – 2018-2021|
|Base year – 2021|
|Expected year – 2022|
|Forecast – 2022-2028|
|Facts covered||Revenue in millions of US dollars|
|Market coverage||North America, Europe, Asia Pacific, Latin America, Middle East and Africa|
|Product/service segmentation||By technique, by disease, by end use, by region|
|Key players||Thermo Fisher Scientific Inc., Alere Inc., Calypte Biomedical Corporation, Chembio Diagnostic Systems, Inc., Meridian Bioscience, Inc., MedMira, Inc., Trinity Biotech plc, Sekisui Diagnostics, OraSure Technologies, Inc., and Quidel Corporation.|
- Side flow
- Agglutination tests
- Flow test
- Molecular diagnostics
- HIV POC
- Clostridium difficile POC
- HBV POC
- Infections associated with pneumonia or Streptococcus
- Respiratory syncytial virus (RSV) POC
- HPV POC
- Influenza/Influenza POC
- HCV POC
- MRSA POC
- Tuberculosis and drug-resistant tuberculosis POC
- HSV (herpes simplex virus) POC
By end use
- At home
- Assisted living health care facilities
- North America
- Asia and the Pacific
- Latin America
- Middle East and Africa
Please see below some new reports:
Orthopedic Navigation Systems Market – Global Size, Share, Trends Analysis, Opportunities and Forecast Report, 2018-2028.
Artificial Cornea and Corneal Implants Market – Global Size, Share, Trends Analysis, Opportunities and Forecast Report, 2018-2028
Clinical Chemistry Analyzers Market – Global Size, Share, Trends Analysis, Opportunities and Forecast Report, 2018-2028.
Urinary Catheters Market – Global Size, Share, Trends Analysis, Opportunities and Forecast Report, 2018-2028.
Peptide and Anticoagulant Drugs Market – Global Industry Size, Share, Trends Analysis and Forecast Report, 2018-2028.
BlueWeave Consulting provides complete Market Intelligence (MI) solutions to businesses across various online and offline products and services. We provide comprehensive market research reports by analyzing both qualitative and quantitative data to improve the effectiveness of your business decisions. BWC has built its reputation from the ground up by providing quality materials and maintaining long-lasting relationships with its customers. We are one of the promising digital MI solution companies providing flexible assistance to make your business ventures successful.
BlueWeave Consulting & Research Pvt. Ltd
+1 866 658 6826 | +1 425 320 4776 | +44 1865 60 0662